Sacutan 24 mg+26 mg (Tablet)
Unit Price: ৳ 45.00 (1 x 10: ৳ 450.00)
Strip Price: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Unimed unihealth pharmaceuticals ltd |
| Also available as |
Indications
- Reduces risk of cardiovascular death and hospitalization for heart failure
- Treatment of symptomatic heart failure in pediatric patients aged one year and older
- Administered in conjunction with other heart failure therapies
- Can be used in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB
Pharmacology
- Contains neprilysin inhibitor, sacubitril
- Contains angiotensin receptor blocker, valsartan
- Inhibits neprilysin via LBQ657
- Blocks angiotensin II type-1 (AT1) receptor via valsartan
- Increases levels of peptides degraded by neprilysin
- Simultaneously inhibits effects of angiotensin II by valsartan
- Inhibits angiotensin II-dependent aldosterone release
Dosage & Administration
- Recommended starting dose for adults: 49/51 mg orally twice daily
- Target maintenance dose for adults: 97/103 mg twice daily
- Starting dose for pediatric patients: based on weight and age
- Adjust pediatric patient doses every 2 weeks, as tolerated by the patient
Interaction
- Should not be used with an ACEi or aliskiren in diabetic patients
- Avoid use with an ARB
- Potassium-sparing diuretics may increase serum potassium level
- NSAIDs may increase risk of renal impairment
- Lithium may increase risk of toxicity
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required in patients with mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
- Recommended starting dose in severe renal impairment: 24/26 mg twice daily
Precautions & Warnings
- May cause angioedema
- Must not be used in patients with a known history of angioedema
- May lower blood pressure and cause symptomatic hypotension
- Monitor serum creatinine
- Monitor serum potassium periodically
- Dosage reduction or interruption may be required for hyperkalemia
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences observed in elderly patients
- Recommendations for severe, mild, and moderate renal impairment
- Recommendations for severe, mild, and moderate hepatic impairment
Overdose Effects
- Hypotension likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children